HPV genotyping panels market set to reach $2.07 billion by 2030

The global market for human papillomavirus genotyping panels is projected to grow from $1.79 billion in 2025 to $2.07 billion by 2030, driven by HPV-related cancer screening, PCR adoption and rising health spending. North America led in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - HPV genotyping panels support earlier detection of HPV strains linked to cervical, oropharyngeal, anal, vulvar and penile cancers. - The market’s growth reflects rising infection rates, broader screening programs and stronger diagnostic lab capacity. - Global cervical cancer burden remains high, with the National Institutes of Health reporting 662,044 new cases and 348,709 deaths in 2022. - The National Institutes of Health said those figures are projected to rise 56.8% and 80.7%, respectively, by 2050.

What happened: - The Business Research Company released a 2026 market report on human papillomavirus (HPV) genotyping panels. - The report values the market at $1.79 billion in 2025 and $1.84 billion in 2026. - The report forecasts the market will reach $2.07 billion by 2030, implying a 3.0% CAGR from 2026 to 2030. - The report also identifies 2.7% CAGR growth between 2025 and 2026. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Widespread HPV infections and growing cervical cancer screening awareness are major growth drivers. - Government-funded screening initiatives are supporting demand for genotyping panels. - Rising use of PCR-based diagnostic methods is adding momentum. - Increased healthcare spending is accelerating adoption of advanced molecular diagnostics. - The American Medical Association reported U.S. health spending rose 7.5% in 2023 to $4.9 trillion, or $14,570 per person. - That followed 4.6% growth in 2022. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market-hotspot infographics and future-trend analysis. - The company said its research library includes more than 30,000 reports across 27 industries and 60 geographies. - The company said it uses 1,500,000 datasets and the Global Market Model forecasting platform. - The release includes a free sample report and the full market report.

Between the lines: - The market thesis is tied less to one product cycle and more to long-term public health demand. - Faster growth in Asia-Pacific suggests room for diagnostic expansion in markets where screening access and healthcare investment are still scaling. - North America’s lead points to mature infrastructure, while future growth may come from broader global adoption rather than a single dominant region.

What's next: - The market is expected to continue rising through 2030 as screening, molecular testing and cancer-detection programs expand. - Healthcare investment and public health funding will likely remain key variables for adoption. - Regional growth patterns will depend on infection prevalence, lab infrastructure and screening coverage. - The Business Research Company is positioning its 2026 report updates around forecasting tools and market-scoring features for buyers tracking the sector.

The bottom line: - HPV genotyping panels are moving from a niche diagnostic tool to a steady-growth market tied to cancer prevention and public health screening.